FDA Approval Insights: Trilaciclib in Extensive-Stage Small Cell Lung Cancer

In our exclusive interview, Weiss discussed the significance of the FDA approval of trilaciclib in extensive-stage small cell lung cancer and key efficacy and safety data that have been reported with the CDK4/6 inhibitor.